Jorge J Castillo
Overview
Explore the profile of Jorge J Castillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
310
Citations
5888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cabrera M, Pena C, Vega V, Rojas H, Pizarro A, Rojas C, et al.
Cancer Rep (Hoboken)
. 2024 Sep;
7(9):e2126.
PMID: 39307921
Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in the United States and Europe. However, data on FL from Latin America are scant. Aims: This study...
12.
Tedeschi A, Tam C, Owen R, Buske C, Leblond V, Dimopoulos M, et al.
Future Oncol
. 2024 Jul;
20(25):1789-1798.
PMID: 39072392
ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and...
13.
Bibas M, Sarosiek S, Castillo J
Mediterr J Hematol Infect Dis
. 2024 Jul;
16(1):e2024061.
PMID: 38984103
Waldenström macroglobulinemia (WM) is an infrequent variant of lymphoma, classified as a B-cell malignancy identified by the presence of IgM paraprotein, infiltration of clonal, small lymphoplasmacytic B cells in the...
14.
Malpica L, Marques-Piubelli M, Beltran B, Chavez J, Miranda R, Castillo J
Am J Hematol
. 2024 Jul;
99(10):2002-2015.
PMID: 38957951
Disease Overview: Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is an aggressive B-cell lymphoma associated with EBV infection included in the WHO classification of...
15.
Zanwar S, Le-Rademacher J, Durot E, DSa S, Abeykoon J, Mondello P, et al.
J Clin Oncol
. 2024 May;
42(21):2527-2536.
PMID: 38788183
Purpose: Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies have emerged since the development of International Prognostic Scoring System, and mutation is now frequently assessed at diagnosis, warranting...
16.
Ramirez-Gamero A, Martinez-Cordero H, Beltran B, Florindez J, Malpica L, Castillo J
Am J Hematol
. 2024 May;
99(8):1586-1594.
PMID: 38767403
Disease Overview: Plasmablastic lymphoma (PBL) is a rare CD20-negative aggressive lymphoma with a poor prognosis under standard treatment options. Though PBL is associated with human immunodeficiency virus infection and other...
17.
Sarosiek S, Castillo J
J Natl Compr Canc Netw
. 2024 May;
22(4).
PMID: 38754469
Bruton tyrosine kinase (BTK) inhibitors have become a standard of care in the treatment of patients with Waldenström macroglobulinemia (WM) and are the only medications approved by the FDA to...
18.
Durot E, Roos-Weil D, Chauchet A, Decroocq J, Di Blasi R, Gastinne T, et al.
Blood
. 2024 Apr;
143(26):2804-2807.
PMID: 38669635
Histologic transformation of Waldenström macroglobulinemia (HT-WM) carries a poor prognosis with standard treatments. Here, we report the first series of HT-WM treated with chimeric antigen receptor T cells showing a...
19.
Itchaki G, Jarhovsky O, Castillo J, Hassan H, Gatt M, Leiba M, et al.
Leuk Lymphoma
. 2024 Mar;
65(7):943-949.
PMID: 38501758
The simultaneous occurrence of Waldenström macroglobulinemia and multiple myeloma in the same patient has been published as case reports. Patients with Waldenström macroglobulinemia often have a small clone of plasma...
20.
Tam C, Opat S, DSa S, Jurczak W, Lee H, Cull G, et al.
Blood Adv
. 2024 Feb;
8(7):1639-1650.
PMID: 38315878
The phase 3 ASPEN trial (NCT03053440) compared Bruton tyrosine kinase inhibitors (BTKis), zanubrutinib and ibrutinib, in patients with Waldenström macroglobulinemia (WM). Post-hoc biomarker analysis was performed using next-generation sequencing on...